Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism
✍ Scribed by Karin Srulijes; Matthias Reimold; Rajka M. Liscic; Sarah Bauer; Elisabeth Dietzel; Inga Liepelt-Scarfone; Daniela Berg; Walter Maetzler
- Book ID
- 102945957
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 1006 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background:
We hypothesized that postural instability and cognitive decline in patients with Richardson's syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe Parkinsonian signs in patients with progressive supranuclear palsy‐parkinsonism may be reflected by alterations in putaminal metabolism.
Methods:
Eleven patients with Richardson's syndrome, 8 patients with progressive supranuclear palsy‐parkinsonism, 12 with Parkinson's disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose positron emission tomography (PET).
Results:
Richardson's syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy‐parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy‐parkinsonism from Richardson's syndrome (area under the curve = 0.86) and from Parkinson's disease (area under the curve = 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson's syndrome patients.
Conclusions:
Richardson's syndrome, progressive supranuclear palsy‐parkinsonism and Parkinson's disease showed different metabolic patterns in fluorodeoxyglucose PET. © 2011 Movement Disorder Society
📜 SIMILAR VOLUMES